Goldman Sachs Group Inc. raised its stake in shares of InVitae Corp (NASDAQ:NVTA) by 165.4% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 54,906 shares of the medical research company’s stock after buying an additional 34,218 shares during the period. Goldman Sachs Group Inc. owned about 0.13% of InVitae Corp worth $525,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Verity Asset Management Inc. boosted its stake in shares of InVitae Corp by 0.8% during the 2nd quarter. Verity Asset Management Inc. now owns 10,607 shares of the medical research company’s stock valued at $101,000 after buying an additional 81 shares during the period. Donald L. Hagan LLC boosted its stake in shares of InVitae Corp by 30.0% during the 2nd quarter. Donald L. Hagan LLC now owns 13,000 shares of the medical research company’s stock valued at $124,000 after buying an additional 3,000 shares during the period. Voya Investment Management LLC boosted its stake in shares of InVitae Corp by 51.2% during the 2nd quarter. Voya Investment Management LLC now owns 16,936 shares of the medical research company’s stock valued at $162,000 after buying an additional 5,733 shares during the period. American International Group Inc. boosted its stake in shares of InVitae Corp by 31.3% during the 1st quarter. American International Group Inc. now owns 17,174 shares of the medical research company’s stock valued at $190,000 after buying an additional 4,090 shares during the period. Finally, Nationwide Fund Advisors boosted its stake in shares of InVitae Corp by 28.6% during the 2nd quarter. Nationwide Fund Advisors now owns 22,020 shares of the medical research company’s stock valued at $211,000 after buying an additional 4,899 shares during the period.

WARNING: This piece was originally reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/11/13/goldman-sachs-group-inc-raises-holdings-in-invitae-corp-nvta.html.

InVitae Corp (NASDAQ:NVTA) opened at $8.62 on Monday. InVitae Corp has a twelve month low of $5.76 and a twelve month high of $11.88.

NVTA has been the subject of a number of research reports. BidaskClub lowered shares of InVitae Corp from a “hold” rating to a “sell” rating in a research note on Wednesday, September 20th. Zacks Investment Research raised shares of InVitae Corp from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. J P Morgan Chase & Co reissued an “overweight” rating and set a $15.00 target price (up previously from $14.00) on shares of InVitae Corp in a research note on Wednesday, August 9th. Finally, Leerink Swann decreased their target price on shares of InVitae Corp from $14.00 to $12.00 and set an “outperform” rating for the company in a research note on Tuesday, November 7th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $13.50.

About InVitae Corp

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Institutional Ownership by Quarter for InVitae Corp (NASDAQ:NVTA)

Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with MarketBeat.com's FREE daily email newsletter.